TY - JOUR
T1 - Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model
AU - Li, Heyan
AU - Wang, Shuo
AU - Takayama, Koichi
AU - Harada, Taishi
AU - Okamoto, Isamu
AU - Iwama, Eiji
AU - Fujii, Akiko
AU - Ota, Keiichi
AU - Hidaka, Noriko
AU - Kawano, Yuko
AU - Nakanishi, Yoichi
N1 - Funding Information:
This study was supported by Research Institute for Diseases of the Chest, Kyushu University (Fukuoka, Japan); and was performed as a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT), Ministry of Education, Culture, Sports, Science and Technology of Japan.
Publisher Copyright:
© 2015 The Authors.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Given our previously published study, α 1 nicotinic acetylcholine receptor (nAChR) plays an essential role in nicotine-induced cell signaling and nicotine-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) PC9 cells. The aim of this study was to investigate the potential mechanism between nAChR and EGFR for nicotine-induced resistance to EGFR-TKI erlotinib in the NSCLC xenograft model. Materials and methods: We identified the role of nicotine to EGFR/AKT/ERK pathways and to erlotinib-resistance in NSCLC PC9 and HCC827 cells by MTS assay and western blot. Then, we established the PC9 xenograft model with nicotine exposure and treated mice with erlotinib combined with vehicle or nicotine. Results: We confirmed the effects of nicotine on EGFR/AKT/ERK pathways and determined nicotine's potential in preventing from the effect of erlotinib on NSCLC cells. Then, we showed that nicotine exposures can promote tumor growth and induce resistance to erlotinib in the PC9 xenograft model. Our results also indicated that chronic oral administration of nicotine can cause more significant erlotinib-resistance compared with acute i.v. injection of nicotine through activating α 1 nAChR and EGFR pathways. Conclusions: These results suggest that nicotine contributes to the progression and erlotinib-resistance of the NSCLC xenograft model via the cooperation between nAChR and EGFR.
AB - Given our previously published study, α 1 nicotinic acetylcholine receptor (nAChR) plays an essential role in nicotine-induced cell signaling and nicotine-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) PC9 cells. The aim of this study was to investigate the potential mechanism between nAChR and EGFR for nicotine-induced resistance to EGFR-TKI erlotinib in the NSCLC xenograft model. Materials and methods: We identified the role of nicotine to EGFR/AKT/ERK pathways and to erlotinib-resistance in NSCLC PC9 and HCC827 cells by MTS assay and western blot. Then, we established the PC9 xenograft model with nicotine exposure and treated mice with erlotinib combined with vehicle or nicotine. Results: We confirmed the effects of nicotine on EGFR/AKT/ERK pathways and determined nicotine's potential in preventing from the effect of erlotinib on NSCLC cells. Then, we showed that nicotine exposures can promote tumor growth and induce resistance to erlotinib in the PC9 xenograft model. Our results also indicated that chronic oral administration of nicotine can cause more significant erlotinib-resistance compared with acute i.v. injection of nicotine through activating α 1 nAChR and EGFR pathways. Conclusions: These results suggest that nicotine contributes to the progression and erlotinib-resistance of the NSCLC xenograft model via the cooperation between nAChR and EGFR.
UR - http://www.scopus.com/inward/record.url?scp=84924529316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924529316&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2015.01.017
DO - 10.1016/j.lungcan.2015.01.017
M3 - Article
C2 - 25670150
AN - SCOPUS:84924529316
SN - 0169-5002
VL - 88
SP - 1
EP - 8
JO - Lung Cancer
JF - Lung Cancer
IS - 1
ER -
